Erythropoietin in pediatric hematology and oncology

被引:0
作者
Witt, V. [1 ]
Zoubek, A. [1 ]
机构
[1] St Anna Childrens Hosp, A-1090 Vienna, Austria
关键词
malignant diseases; anemia; blood transfusion; erythropoietin; children and adolescents;
D O I
10.1007/s00112-007-1623-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Of children and adolescents with malignant diseases, 80% are already anemic at the time of diagnosis. The pathophysiology of the development of anemia by malignant diseases is complex. Although anemia represents a potentially life threatening complication, less attention is paid to the effect on the physical, psychological and social status of the children. The main therapy option is a blood transfusion, which is immediately effective but has, however, a limited duration of effectiveness. In addition there is a risk of undesired acute and chronic transfusion reactions, in particular from infectious complications. Erythropoietin has been used successfully for 25 years as an adjunct to cure or alleviate anemia due to malignant diseases in adulthood. Since the middle of the 1990s several well-structured studies have been carried in childhood and adolescence. The question is, whether erythropoietin should also be considered a preferred alternative for the treatment of anemia by malignant diseases in children and adolescents.
引用
收藏
页码:1150 / +
页数:7
相关论文
共 28 条
[11]   Molecular pathogenesis of anemia of chronic disease [J].
Ganz, T .
PEDIATRIC BLOOD & CANCER, 2006, 46 (05) :554-557
[12]   Use of human recombinant erythropoietin in children with cancer [J].
Guyot, D ;
Margueritte, G .
ARCHIVES DE PEDIATRIE, 2005, 12 (09) :1376-1382
[13]   Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy [J].
Henry, David H. ;
Dahl, Naomi V. ;
Auerbach, Michael ;
Tchekmedyian, Simon ;
Laufman, Leslie R. .
ONCOLOGIST, 2007, 12 (02) :231-242
[14]   Defective erythropoiesis in bone marrow is a mechanism of anemia in children with cancer [J].
Kim, M ;
Lee, J ;
Wu, C ;
Cho, S ;
Lee, K .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2002, 17 (03) :337-340
[15]   Reduction in transfusion requirements with early epoetin alfa treatment in pediatric patients with solid tumors: A case-control study [J].
Kronberger, M ;
Fischmeister, G ;
Poetschger, U ;
Gadner, H ;
Zoubek, A .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2002, 19 (02) :95-105
[16]  
Leon P, 1998, MED PEDIATR ONCOL, V30, P110, DOI 10.1002/(SICI)1096-911X(199802)30:2<110::AID-MPO8>3.0.CO
[17]  
2-L
[18]   A randomized controlled study of iron supplementation in patients treated with erythropoietin [J].
Macdougall, IC ;
Tucker, B ;
Thompson, J ;
Tomson, CRV ;
Baker, LRI ;
Raine, AEG .
KIDNEY INTERNATIONAL, 1996, 50 (05) :1694-1699
[19]   Incidence of anemia in pediatric cancer patients in Europe: Results of a large, international survey [J].
Michon, J .
MEDICAL AND PEDIATRIC ONCOLOGY, 2002, 39 (04) :448-450
[20]   Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy [J].
Razzouk, Bassem I. ;
Hord, Jeffrey D. ;
Hockenberry, Marilyn ;
Hinds, Pamela S. ;
Feusner, James ;
Williams, Denise ;
Rackoff, Wayne R. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) :3583-3589